# Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis

> **NCT04707703** · PHASE3 · TERMINATED · sponsor: **Jeffrey Jenks, MD, MPH** · enrollment: 8 (actual)

## Conditions studied

- Severe Acute Respiratory Syndrome Coronavirus 2
- Aspergillosis Invasive

## Interventions

- **DRUG:** Isavuconazonium Injection [Cresemba]
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04707703
- **Lead sponsor:** Jeffrey Jenks, MD, MPH
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-16
- **Primary completion:** 2021-10-25
- **Final completion:** 2021-10-25
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Participant enrollment challenges
- **Last updated:** 2022-11-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04707703

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04707703, "Isavuconazole for the Prevention of COVID-19-associated Pulmonary Aspergillosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04707703. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*